Why are pain management clinics hesitant to treat patients who use Tetrahydrocannabinol (THC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pain management clinics are hesitant to treat patients who use THC primarily due to concerns about drug interactions, regulatory compliance, and treatment efficacy. According to a recent study published in the British Journal of Anaesthesia 1, the clinical effects of cannabis, including THC, can vary greatly depending on the quantity consumed and chronicity of use, affecting many organ systems, including the CNS, cardiovascular system, and respiratory system. This complexity can make it challenging for healthcare providers to design effective treatment plans.

Some key concerns include:

  • Drug interactions: THC can potentially interact with opioid medications and other pain treatments, altering their effectiveness or increasing sedation risks 1.
  • Regulatory compliance: Clinics must comply with federal regulations, as marijuana remains a Schedule I controlled substance under federal law, regardless of state legalization.
  • Treatment efficacy: THC use can complicate pain assessment and treatment monitoring, as it may mask or alter pain perception.
  • Liability issues: Clinics may worry about potential liability issues if adverse events occur in patients using both prescribed pain medications and THC.
  • Limited standardized dosing information: There is a lack of standardized dosing information for THC products, making it difficult for providers to account for its effects when designing treatment plans 1.

Patients who use THC should be transparent with their healthcare providers about their usage to ensure safe and effective pain management. By understanding the potential risks and complexities associated with THC use, healthcare providers can work with patients to develop personalized treatment plans that prioritize their safety and well-being.

From the Research

Pain Management and THC Use

  • Pain management clinics may be hesitant to treat patients who use Tetrahydrocannabinol (THC) due to various reasons, including the lack of comprehensive research on the long-term effects of THC on pain management 2, 3.
  • However, studies have shown that medical cannabis, which contains THC, can be effective in managing chronic nonmalignant pain 2, 4.
  • The endocannabinoid system plays a crucial role in modulating pain perception, and THC has been found to decrease nociception and symptom frequency via this system 2, 5.
  • Despite the potential benefits of THC in pain management, its use is still classified as a schedule one drug by the Drug Enforcement Agency (DEA), which limits research on its therapeutic effects 2.

Clinical Evidence and Safety Concerns

  • Clinical studies have demonstrated that neuropathic pain patients can derive benefits from cannabinoid treatment, including subjective and objective measures of pain relief 4, 5.
  • However, the safety of cannabis use for medical purposes has not been systematically evaluated, and there is a need for comprehensive risk-benefit discussions 3, 6.
  • A prospective cohort study found that medical cannabis users were at increased risk of non-serious adverse events, but there was no difference in risk of serious adverse events compared to controls 6.
  • The study also found that quality-controlled herbal cannabis, when used by patients with experience of cannabis use as part of a monitored treatment program, appears to have a reasonable safety profile 6.

Limitations and Future Research

  • The current evidence base for the use of THC in pain management is limited, and additional research is needed to support or refute its therapeutic effects 2, 3.
  • Further studies are required to evaluate the long-term effects of THC on pain management and to address the safety concerns associated with its use 3, 6.
  • The development of pharmacological interventions to reduce the drawbacks of existing chemotherapeutics and counter neuropathic pain is an urgent unmet clinical need, and cannabinoids may play a role in addressing this need 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Medical Cannabis for Chronic Nonmalignant Pain Management.

Current pain and headache reports, 2023

Research

Cannabis and Pain: A Clinical Review.

Cannabis and cannabinoid research, 2017

Research

Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009

Research

Applications of Cannabinoids in Neuropathic Pain: An Updated Review.

Critical reviews in therapeutic drug carrier systems, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.